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INTRODUCTION
Endochondral bone formation is a key regulatory event affecting
several aspects of skeletal development, such as longitudinal growth
and the formation of the thoracic cavity, which are essential for
movement and respiration in vertebrates (de Crombrugghe et al.,
2001; Kronenberg, 2003; Karsenty et al., 2009). A crucial step in the
process of endochondral bone formation is chondrocyte
differentiation. The importance of this step is evident from the
severe skeletal dysplasia diseases that result from mutations
affecting chondrocyte differentiation (Ornitz, 2005).
Chondrocytes develop through a series of sequential steps (de
Crombrugghe et al., 2001; Kronenberg, 2003; Lefebvre and Smits,
2005). First, mesenchymal cells migrate to the location in which the
future skeleton will be formed (Hall and Miyake, 2000). They then
gather close to each other to form mesenchymal condensations, after
which they begin to produce chondrocyte-specific extracellular
matrix components such as a1(II) collagen (Col2a1 – Mouse
Genome Informatics) (cartilaginous anlagen). At this stage they are
recognized as chondroblasts. Finally, chondroblasts differentiate into
proliferative chondrocytes, which eventually mature into
hypertrophic chondrocytes.
Since the beginning of the 1990s, much progress has been made in
understanding the transcriptional control of chondrogenesis (Lefebvre
and Smits, 2005; Karsenty et al., 2009). Sox9 is essential for the
differentiation of mesenchymal cells into chondroblasts, as shown by
the fact that mice lacking Sox9 possess no chondrocytes (Bi et al.,
1999; Akiyama et al., 2002). In addition, Sox5 and Sox6, which are
expressed after mesenchymal condensations are formed, induce the
differentiation of chondroblasts into chondrocytes in combination
with Sox9 (Lefebvre et al., 1998; Ikeda et al., 2004). Indeed, Sox5–/–;
Sox6–/– mice undergo normal mesenchymal condensation; however,
these cells do not further differentiate into chondrocytes (Smits et al.,
2001). Interestingly, the expression of Sox5 and Sox6 is abolished in
mice lacking Sox9, in contrast to the normal expression of Sox9 in
Sox5–/–; Sox6–/– mice (Smits et al., 2001; Akiyama et al., 2002). This
result indicates that Sox9 is genetically upstream of Sox5 and Sox6;
however, the molecular mechanism for the induction of Sox5 and Sox6
remains to be elucidated.
Once cells are committed to the chondrocyte lineage, Runx2, a
master regulator of osteoblast differentiation (Stein et al., 2004;
Karsenty et al., 2009), induces chondrocyte hypertrophy directly
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SUMMARY
Chondrocyte differentiation is strictly regulated by various transcription factors, including Runx2 and Runx3; however, the
physiological role of Runx1 in chondrocyte differentiation remains unknown. To examine the role of Runx1, we generated
mesenchymal-cell-specific and chondrocyte-specific Runx1-deficient mice [Prx1 Runx1f/f mice and a1(II) Runx1f/f mice, respectively] to
circumvent the embryonic lethality of Runx1-deficient mice. We then mated these mice with Runx2 mutant mice to obtain
mesenchymal-cell-specific or chondrocyte-specific Runx1; Runx2 double-mutant mice [Prx1 DKO mice and a1(II) DKO mice,
respectively]. Prx1 Runx1f/f mice displayed a delay in sternal development and Prx1 DKO mice completely lacked a sternum. By
contrast, a1(II) Runx1f/f mice and a1(II) DKO mice did not show any abnormal sternal morphogenesis or chondrocyte differentiation.
Notably, Runx1, Runx2 and the Prx1-Cre transgene were co-expressed specifically in the sternum, which explains the observation
that the abnormalities were limited to the sternum. Histologically, mesenchymal cells condensed normally in the prospective
sternum of Prx1 DKO mice; however, commitment to the chondrocyte lineage, which follows mesenchymal condensation, was
significantly impaired. In situ hybridization analyses demonstrated that the expression of a1(II) collagen (Col2a1 – Mouse Genome
Informatics), Sox5 and Sox6 in the prospective sternum of Prx1 DKO mice was severely attenuated, whereas Sox9 expression was
unchanged. Molecular analyses revealed that Runx1 and Runx2 induce the expression of Sox5 and Sox6, which leads to the
induction of a1(II) collagen expression via the direct regulation of promoter activity. Collectively, these results show that Runx1 and
Runx2 cooperatively regulate sternal morphogenesis and the commitment of mesenchymal cells to become chondrocytes through
the induction of Sox5 and Sox6.
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through its expression in nonhypertrophic chondrocytes or represses
chondrocyte hypertrophy through its expression in the bone collar
(Takeda et al., 2001; Hinoi et al., 2006). Mice overexpressing Runx2
in chondrocytes show ectopic chondrocyte hypertrophy in places
where hypertrophic chondrocytes do not normally exist (Takeda et
al., 2001; Sato et al., 2008). By contrast, Runx2–/– mice exhibit
abnormal chondrocyte hypertrophy in most skeletal elements except
the distal limbs (Komori et al., 1997). Runx3, another member of the
Runx family, also regulates chondrocyte hypertrophy in cooperation
with Runx2 (Yoshida et al., 2004); however, the role of Runx1 in
chondrocyte differentiation in vivo has never been addressed. In this
study we addressed the role of Runx1 at various stages of
chondrocyte differentiation using tissue- and stage-specific Runx1-
deficient mice. Our results demonstrate that Runx1, in cooperation
with Runx2, is essential for the commitment of mesenchymal cells
to the chondrocyte lineage through the induction of Sox5 and Sox6.
MATERIALS AND METHODS
Generation of Runx1 conditional knockout mice
To generate Runx1-floxed mice, targeting vectors harboring loxP sites as
well as a floxed neomycin resistance cassette were electroporated into
embryonic stem (ES) cells (for details, see Fig. S1 in the supplementary
material). ES cells containing the floxed allele (after NeoR removal) were
injected into 129Sv/EV blastocysts to generate chimeric mice. Runx1f/+ mice
were crossed with Prx1 (Prrx1 – Mouse Genome Informatics) Cre or a1(II)
Cre mice (Martin and Olson, 2000; Takeda et al., 2001) to generate Prx1 Cre
Runx1f/+ mice or a1(II) Cre Runx1f/+ mice, respectively, and their progeny
were intercrossed to obtain Prx1 Cre Runx1f/f mice or a1(II) Cre Runx1f/f
mice. All genotypes were determined using PCR. Runx2–/– mice have been
described previously (Otto et al., 1997). We maintained all mice under a 12-
hour light:dark cycle with ad libitum access to regular food and water.
All animal experiments were performed with the approval of the Animal
Study Committee of the Tokyo Medical and Dental University and
conformed to relevant guidelines and laws.
Skeletal analysis, lacZ staining and whole-mount in situ
hybridization analysis
For skeletal preparations, mice were dissected, fixed in 95% ethanol and
stained with Alcian Blue and Alizarin Red according to standard protocols
(McLeod, 1980). At least six mice were analyzed for each genotype. For lacZ
staining, skinned and eviscerated animals were fixed in 1% paraformaldehyde
and 0.2% glutaraldehyde in phosphate buffer at pH 7.3 and stained overnight
with 5-bromo-4-chloro-3-indoyl b-D-galactopyranoside (X-gal) (Sato et al.,
2008). Whole-mount in situ hybridization analysis was performed as
previously described (Iseki et al., 1999).
Histological and in situ hybridization analysis
Embryos and pups were fixed in 4% paraformaldehyde/PBS overnight at 4°C
and processed for paraffin embedding, and 5 mm sections were cut. The
sections were stained with Alcian Blue and Nuclear Fast Red. Peanut
agglutinin (PNA) staining was performed as previously described (Delise et
al., 2002). Briefly, sections were dewaxed, rehydrated, incubated with
biotinylated PNA (Vector Laboratories) at 100 mg/ml and then washed with
PBS. Bound PNA was detected using the TSA-Biotin System (Perkin Elmer)
and DAB substrate (Vector Laboratories) according to the manufacturer’s
instructions. We analyzed six mice per genotype. We performed in situ
hybridization analysis as previously described (Sato et al., 2007). The Sox9,
Sox5 and Sox6 probes were obtained from Dr Haruhiko Akiyama (Kyoto
University, Kyoto, Japan). The a1(II) collagen probe was previously
described (Takeda et al., 2001). We stained sections hybridized with 35S-
labeled riboprobes. Hybridizations were performed overnight at 55°C, and
washes were performed at 63°C. We analyzed three mice per genotype.
Cell culture and transfection
HeLa and C3H101/2 cells were grown in DMEM with 10% FBS and 1%
GPS. Lipofectamine LTX (Invitrogen) or Hyperfect (Qiagen) was used for
transient DNA or siRNA transfection, respectively, according to the
manufacturer’s instructions. Runx1 bioactivity was verified by co-
transfection of HeLa cells with a Runx1-responsive-Sox6 promoter
luciferase reporter construct, a Renilla luciferase expression plasmid and a
Runx1 expression vector. After 48 hours, luciferase activity was measured.
The data are presented as the ratio of Firefly luciferase activity to Renilla
luciferase activity, and the values are the mean of six independent
transfection experiments. We performed all cell culture experiments in
triplicate or quadruplicate wells and repeated the experiments at least four
times.
Quantitative real-time PCR analysis
Real-time PCR analysis was performed using total RNA treated with DNase
I. We extracted RNA with Trizol (Invitrogen) and performed reverse
transcription to synthesize cDNA according to the manufacturer’s
instructions (Sato et al., 2008). We performed quantitative analysis of gene
expression using the Mx3000P Real-Time PCR System (Stratagene). The
primer sequences are available upon request. We used Gapdh expression as
an internal control.
Electrophoretic mobility shift assay and chromatin
immunoprecipitation assay
Nuclear extracts of Runx1- or Runx2-expressing COS cells were incubated
with a labeled Sox6 probe at 4°C for 40 minutes. For the super-shifting
experiments, 1 mg of anti-Runx1 (C-19X) or Runx2 (M-70X) antibody
(Santa Cruz Biotechnology) was added to the reaction. Chromatin
immunoprecipitation (ChIP) was performed according to the manufacturer’s
instructions (Diagenode), using HeLa cells that had been transfected with
Runx1-GFP or GFP as a control, untransfected C3H10T/12 cells and naïve
mouse sternal anlagen. We used the following PCR primers; primers
spanning the Runx-binding site of the human Sox6 promoter (–585/–389):
forward 5-CCCCCCGTTTTTGGACAGTA-3 and reverse 5-GAC -
TCCCTGGCGAAGTCC-3. Control primers not spanning the Runx-
binding site (–1663/–1144): forward 5-TCCGTGAAGTTCGAGGTAGG-
3 and reverse 5-GCGGCGGTAACAAGAGATAC-3. Primers spanning
the Runx-binding site of the mouse Sox6 promoter (–498/–287): forward 5-
TCAGCAGTACACAAACCGAACT-3 and reverse 5-AGAGCCTAG -
AGGGACGAAGGT-3). Control primers not spanning the Runx-binding
site (–1546/–1385): forward 5-TTCCTCC CCTCTCTCCCTTT-3 and
reverse 5-CTCAAAACCCAAGCAAGCAT-3. We isolated sternal
anlagen as previously described (Zhang et al., 2004) with modifications.
Briefly, the ventral rib cage was dissected from embryonic day 12.5 (E12.5)
mouse embryos and digested with Dispase (1 U/ml) (Invitrogen) for 10
minutes to remove soft tissue. The remaining sternal anlagen was then
manually separated, collected and digested for 20 minutes to obtain single-
cell suspensions.
Statistical analysis
All data are presented as the mean±s.d. (n=6 or more). Statistical
significance was assessed using Student’s t-test. Values were considered
statistically significant at P<0.05. The results are representative of at least
four individual experiments.
RESULTS
Absence of a sternum in mice lacking Runx1 in
undifferentiated mesenchymal progenitor cells
Runx1 is a pivotal transcription factor for the generation of
hematopoietic stem cells (Ito, 2004), and Runx1-null mice die
around E11.5, which is an insurmountable obstacle in the study of
its role in chondrocyte differentiation. Therefore, we generated
mesenchymal-cell-specific and chondrocyte-specific Runx1-
deficient mice to examine the role of Runx1 during different stages
of chondrocyte differentiation. To this end, we first generated
Runx1-floxed mice (Runx1f/f mice), in which exon 4 of the Runx1
gene was flanked by loxP sites. This region encodes a runt domain,
which is indispensable for DNA binding and the interaction with
core binding factor beta, an essential partner for functional
transcriptional activity (Ito, 2004) (see Fig. S1 in the supplementary











material). We then inactivated Runx1 in undifferentiated
mesenchymal progenitor cells using Prx1-Cre transgenic (tg) mice
to obtain Prx1-Cre tg/Runx1f/f mice (hereafter, Prx1 Runx1f/f mice)
(Logan et al., 2002). The Prx1-Cre transgene is expressed in
mesenchymal cells of the limbs, head and sternum (see Fig. 2C and
data not shown) (Logan et al., 2002). Prx1 Runx1f/f mice were viable
and were born in the expected Mendelian ratio. To study skeletal
development, we first performed Alcian Blue/Alizarin Red staining
of skeletal preparations. This analysis showed that in contrast to
wild-type mice, the xiphoid process was not yet mineralized, i.e. was
not stained by Alizarin Red in 91% of the newborn Prx1 Runx1f/f
mice (21/23 newborns) (Fig. 1A). There was also a delay in sternal
development at the age of 2 weeks (5/5 mice) (see Fig. S2 in the
supplementary material); however, when the mice were analyzed at
3 weeks of age, this defect was not observed (4/5 mice) (see Fig. S2
in the supplementary material). No other skeletal elements of the
Prx1 Runx1f/f mice showed any abnormalities, and no growth
retardation was observed (Fig. 1A and data not shown). Importantly,
the columnar structure in the growth plate of the femur of Prx1
Runx1f/f mice was indistinguishable from that of wild-type mice
(data not shown). Taken at face value, these results suggest that
Runx1 alone, or in combination with other members of the Runx
family of transcription factors, may play a transient role during the
formation of the sternum. Because Runx2 is also important for
chondrocyte differentiation (Takeda et al., 2001), we next
determined whether Runx2 was compensating for the loss of Runx1
by breeding Prx1 Runx1f/f mice with Runx2 mutant mice to generate
Prx1 Runx1f/f/Runx2–/– mice (hereafter, Prx1 DKO mice). Prx1
DKO mice were non-viable, similar to Runx2–/– mice; therefore, the
analysis was made on embryos and newborns. As previously shown,
no mineralization was observed in most of the skeletal elements,
including the sternum of Runx2–/– mice (Fig. 1A) (Komori et al.,
1997). Surprisingly, skeletal preparations of newborn mice showed
that all of the Prx1 DKO mice completely lacked sternums (9/9
newborns), and their internal organs were protruded, which is in
sharp contrast to the normal sternal fusion seen in Prx1 Runx1f/f mice
and Runx2–/– mice (Fig. 1A,B). These results suggest that Runx1, in
cooperation with Runx2, regulates the development of the sternum.
Beginning around E12.5, the sternum starts to develop from
mesenchymal cells as they form two cartilaginous processes called
sternal bars (see Fig. S3 in the supplementary material) (Chen,
1952). Subsequently, these sternal bars migrate ventrally and fuse
craniocaudally to form the sternum (see Fig. S3 in the
supplementary material) (Chen, 1952). Histological analysis
revealed that wild-type mice, Prx1 Runx1f/f mice and Runx2–/– mice
had completed sternal fusion by birth (Fig. 1B). By contrast, there
was no sign of sternal bar development in Prx1 DKO mice, even at
birth (Fig. 1A,B). Interestingly, in Prx1 Runx1f/f mice and Runx2–/–
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Fig. 1. Sternal abnormality in mesenchymal-specific
Runx1-deficient mice. (A,C,D) Skeletal preparation of
newborn mice. (A) Note the delay in calcification of the
xiphoid process in Prx1 Runx1f/f mice (arrowhead) and the
absence of the sternum in Prx1 DKO mice. By contrast,
the sternal bars of Runx2–/– mice are fused by birth, yet
their xiphoid processes are non-mineralized. (A,C) Prx1
Runx1f/f/Runx2+/– mice show an intermediate phenotype
between Prx1 Runx1f/f mice and Prx1 DKO mice
(arrowhead). (A,D) Prx1 Runx1f/+/Runx2–/– mice show an
intermediate phenotype between Runx2–/– mice and Prx1
DKO mice (arrowhead). (B) Histological analysis of mouse
embryo sternums. Axial section. Note the absence of the
sternum and the protrusion of internal organs in Prx1
DKO mice. Prx1 Runx1f/f mice and Prx1 DKO mice denote
Prx1 Cre; Runx1f/f mice and Prx1 Cre; Runx1f/f; Runx2–/–













mice, sternal bar development was moderately delayed, with the two
sternal bars remaining apart at E14.5, whereas the sternums of wild-
type embryos at that stage had started to fuse, further indicating the
complementary roles of Runx1 and Runx2 (Fig. 1B). In line with
this finding, all of the Prx1 Runx1f/+; Runx2–/– mice (6/6 mice)
showed more severe abnormalities than Runx2–/– mice, and removal
of one copy of Runx2 from the Prx1 Runx1f/f mice (i.e. 8/8 Prx1
Runx1f/f/Runx2+/– mice) exaggerated the abnormality of Prx1
Runx1f/f mice, even though the development of the sternum was
normal in Runx2+/– mice (Fig. 1A,C,D; see Fig. S2 in the
supplementary material). Taken together, these results demonstrate
that Runx1 and Runx2 cooperatively regulate sternal development.
Expression of Runx genes in skeletal elements
The sternum-restricted skeletal abnormalities in Prx1 DKO mice
prompted us to analyze the expression of the Runx genes and the
Prx1-Cre transgene. As detected in whole-mount in situ
hybridization analyses, Runx1 was strongly expressed in the sternal
bars at E12.5 and 13.5, and its expression decreased thereafter (Fig.
2A and data not shown). By contrast, little expression was detected
in the limbs (Fig. 2A). Runx2 was expressed in the sternal bars,
clavicles, ribs and limbs (Fig. 2A). The expression of Runx2 in the
sternal bars was also verified using lacZ staining of Runx2+/– mice
in which the lacZ allele had been inserted in the genomic Runx2
locus (Fig. 2B) (Otto et al., 1997). By contrast, Runx3 was expressed
only in the limbs and not in the sternum at E12.5 and 13.5 (Fig. 2A).
To analyze the expression of the Prx1-Cre transgene, Prx1 Cre tg
mice were crossed with Rosa26 reporter mice (Soriano, 1999). As
detected using lacZ staining, expression of the transgene was
observed in the sternal bars, ventral rib cage and limbs at E12.5 and
thereafter by lacZ staining (Fig. 2C). Thus, the only common region
where Runx1 and the Prx1-Cre transgene were co-expressed was the
sternum. This pattern of co-expression explains why the
abnormalities in the Prx1 DKO mice were restricted to the sternum.
Interestingly, the distal long bones in Runx2–/– mice remained
calcified after the deletion of Runx1 in Prx1 DKO mice (Fig. 1A),
whereas they disappeared in Runx2–/–/Runx3–/– mice (Yoshida et al.,
2004). This result suggests that distinct expression patterns define
the specific role of each Runx gene in skeletal development.
Normal cartilage development in mice lacking
Runx1 in committed chondrocytes
We next examined the role of Runx1 in cells committed to the
chondrocyte lineage after the formation of mesenchymal
condensations by analyzing a1(II)-Cre tg/Runx1f/f mice (hereafter,
a1(II) Runx1f/f mice) (Terpstra et al., 2003).
At birth and at all other stages analyzed, there were no overt
abnormalities in the a1(II) Runx1f/f mice (13/13 a1(II) Runx1f/f
mice) (Fig. 3A). The length of the femur was comparable between
wild-type and a1(II) Runx1f/f mice (data not shown), and the
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Fig. 2. Expression of the Runx genes, the Prx1-Cre
transgene and the a1(II) collagen-Cre transgene
during skeletal development. (A) Whole-mount in
situ hybridization analysis of the Runx genes and Sox9 in
E12.5 and 13.5 mouse embryos. Runx1 and Runx2, but
not Runx3, are expressed in the prospective sternum.
(B) lacZ staining analysis of Runx2+/– mice. Note the
distinct expression of Runx2 as shown by positive blue
staining in the prospective sternum. (C) lacZ staining of
Prx1-Cre; Rosa26 reporter and a1(II)-Cre; Rosa26
reporter embryos. Note that the Prx1-Cre transgene is
expressed as early as E12.5 in the prospective sternum,
whereas the a1(II)-Cre transgene is expressed only after
E13.5. Expression of the Prx1-Cre transgene was also
observed in the ventral, but not dorsal (arrows), rib cage
from E12.5 to birth (P0). Arrowheads indicate the future












columnar structure of the growth plate was indistinguishable (Fig.
3B). Moreover, the sternum was morphologically normal, and there
was no sign of delay in mineralization or abnormalities in
hypertrophic chondrocyte maturation, as observed by skeletal
staining and histological analysis (Fig. 3A and data not shown), even
though the a1(II)-Cre transgene was expressed in the sternum (Fig.
2C). This observation is in sharp contrast to the delayed
mineralization of the sternum in Prx1 Runx1f/f mice, further
suggesting a requirement for Runx1 in early sternal development.
We also generated a1(II) Runx1f/f/Runx2–/– mice (hereafter, a1 (II)
DKO mice); however, there were no overt differences between
Runx2–/– mice and a1(II) DKO mice (6/6 a1(II) DKO mice) (Fig.
3A,B). Collectively, these results suggest that Runx1 does not play
a major role in chondrocyte differentiation once the cells are
committed to becoming chondrocytes.
Runx1 is essential for the differentiation of
mesenchymal cells into chondrocytes
Although both the Prx1-Cre and the a1(II)-Cre transgenes were
expressed in the sternum (Fig. 2C), only Prx1 DKO mice developed
a sternal defect, suggesting that Runx1 is important at a stage when
Prx1 is expressed and a1(II) collagen is not, namely, early in
chondrocyte development (Fig. 2C). Therefore, we focused our
analysis on an early stage of sternal development. Around E12.5 the
sternal rudiment first appears as a pair of mesodermal condensations
in the dorsolateral body wall at the level of the upper ribs (see Fig.
S3 in the supplementary material) (Chen, 1952). At E13.5, the
sternal bars form more distinct structures: they are still located near
the distal ends of the ribs, but a clear boundary is observed between
the sternal bars and the rib ends (Fig. 4A; see Fig. S3 in the
supplementary material) (Chen, 1952). In the sternal bars of E13.5
embryos, precartilaginous mesenchymal condensations were
observed irrespective of deficiencies in Runx1 or Runx2, as
evidenced by the dense packing of mesenchymal cells and also by
PNA staining (Fig. 4A) (Delise et al., 2002). Importantly, weak
Alcian Blue staining in Prx1 DKO mice revealed that less
cartilaginous matrices were produced in these mice compared with
wild-type mice, indicating that chondrocyte differentiation was
impaired (Fig. 4A). We next analyzed molecular markers of
chondrocyte differentiation. Sox9, which is an essential transcription
factor for chondrocyte differentiation and is also known as a marker
of mesenchymal condensation (Lefebvre et al., 1998; Akiyama et
al., 2002), was expressed in the sternal bars of Prx1 DKO mice at a
level comparable to that in wild-type mice, Prx1 Runxf/f mice and
Runx2–/– mice. By contrast, the expression of Sox5 and Sox6, Sox9-
dependent transcription factors necessary for chondrocyte
differentiation (Smits et al., 2001), was significantly reduced in Prx1
DKO mice (Fig. 4B). Furthermore, the expression of a1(II) collagen
was reduced to background levels in Prx1 DKO mice (Fig. 4B).
Importantly, TUNEL staining revealed no apoptotic cell death,
indicating that increased cell death was not responsible for the
abnormal sternal development (see Fig. S4 in the supplementary
material). This result is in agreement with the poor chondrocyte
proliferation without an increase in the cell death of chondroblasts
observed in Sox5–/–; Sox6–/– mice. Collectively, these results show
that chondrocyte differentiation in Prx1 DKO mice is hampered at
the condensation stage, possibly as a result of impaired expression
of Sox5 and Sox6.
Sox6 is a molecular target of Runx1 during
chondrogenesis
The decrease in Sox5 and Sox6 expression in Prx1 DKO mice
indicated that Runx1 and Runx2 might regulate the expression of
Sox5 and Sox6 in chondrocytes. To address this possibility, we
overexpressed Runx1 or Runx2 in the mesenchymal-chondrogenic
cell line C3H10T1/2 to determine whether either protein induced the
expression of Sox5 or Sox6. Indeed, the expression of Sox5 and
Sox6, but not Sox9, was clearly induced by the overexpression of
Runx1 or Runx2 (Fig. 5A). Moreover, both proteins upregulated
a1(II) collagen expression, i.e. induced chondrogenesis (Fig. 5A).
Surprisingly, ectopic expression of Runx1 or Runx2 in non-
mesenchymal HeLa cells also induced Sox5 and Sox6 expression
(data not shown). Collectively, these results demonstrate that Runx1
and Runx2 have a potent ability to induce chondrocyte
differentiation. However, knockdown of Runx1 and Runx2 in
mesenchymal-chondrogenic C3H10T1/2 cells significantly
decreased Sox5 and Sox6 expression (Fig. 5B; see Fig. S5 in the
supplementary material). We searched in silico for potential Runx1-
binding sites in the Sox6 promoter and found a consensus binding
sequence for runt-related transcription factors (Fig. 5C). Of note, this
binding site is conserved across several species (Fig. 5C). To study
the role of this binding site in the Runx1- or Runx2-mediated
induction of Sox6, we first performed an electrophoretic mobility
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Fig. 3. Normal chondrocyte differentiation in committed
chondrocyte-specific Runx1-deficient mice. (A) Skeletal preparations
of newborn mice. (B) Histological sections of femurs from newborn
mice. Sections were stained with Alcian Blue and Nuclear Fast Red
stain; extracellular cartilage matrix is stained blue. There are no overt
differences between wild-type and a1(II)-Cre; Runx1f/f mice or between
Runx2–/– mice and a1(II)-Cre DKO mice. a1(II) Runx1f/f mice and a1(II)
DKO mice denote a1(II)-Cre; Runx1f/f mice and a1(II)-Cre; Runx1f/f;












shift assay (EMSA) using double-stranded oligonucleotides that
covered the potential binding site as a probe. A protein-DNA
complex was formed upon incubation of a nuclear extract from
Runx1-expressing cells and the probe (Fig. 5D). This complex was
not observed with mutated probes or with the addition of unlabeled
probes (Fig. 5D). Moreover, an antibody against Runx1 supershifted
this DNA-protein complex, demonstrating that Runx1 binds to the
Sox6 promoter (Fig. 5D). Similar results were obtained using
recombinant Runx2 protein and an anti-Runx2 antibody (Fig. 5D).
We next performed ChIP. An antibody against Runx1 successfully
immunoprecipitated the region containing the Runx1 binding site,
whereas control serum did not, confirming that Runx1 binds to this
site in vivo (Fig. 6A). We also performed ChIP analysis using an
antibody against Runx2 and obtained similar results (Fig. 6A).
Moreover, using untransfected C3H10T1/2 cells and naïve mouse
primary sternal anlagen, we observed that endogenous Runx1 and
Runx2 bind to the Sox6 promoter in vivo (Fig. 6A).
To address the importance of this site for Sox6 promoter activity,
we performed DNA transfection experiments using a 0.5 kb Sox6
promoter construct containing a Runx binding site fused with a
luciferase reporter (pSox6-luc) (Ikeda et al., 2007). Runx1
expression induced the luciferase expression 7.1-fold compared with
the control, and mutation or deletion of the Runx binding site
decreased expression by 50% (Fig. 6B). These results suggest that
Runx1 and Runx2 regulate Sox6 promoter activity through this site.
Collectively, these results clearly demonstrate that Sox6 is a bona
fide transcriptional target of Runx1 and Runx2.
DISCUSSION
In this study we demonstrate that Runx1 and Runx2 act
cooperatively to promote sternal morphogenesis. We also
demonstrate that Runx1 is dispensable for chondrocyte maturation
once cells are committed to the chondrocyte lineage. Lastly, we
found that Runx1 and Runx2 regulate the transcription of Sox5 and
Sox6, leading to normal chondrogenesis and sternal development.
It has previously been reported that Runx1 induces chondrocyte
differentiation in vitro (Wang et al., 2005). The physiological role of
Runx1 in chondrocyte differentiation in vivo, however, including
any temporal or spatial requirements, was not clear. This study
presents the first in vivo evidence of the role of Runx1 in sternal
development and chondrocyte differentiation and identifies Sox6 as
a molecular target of Runx1 and Runx2 in this process (Fig. 6C).
Molecular dissection of sternal morphogenesis
The sternum, like the forelimbs, develops from the lateral body wall,
whereas the dorsal ribs develop from the axial mesoderm, specifically
from somites and perichordal tissue. Indeed, the Prx1 gene, which is
well known for its strong expression in the limbs, is also expressed in
sternal rudiments but not in the dorsal ribs. Even though sternal
malformations are sometimes observed in human genetic disorders
and mutant mouse models (Wurst et al., 1994; Storm and Kingsley,
1996; Katagiri et al., 1998; Shalak et al., 2002), the complete absence
of the sternum is a relatively rare occurrence (Shalak et al., 2002).
Moreover, the genetic pathway regulating sternal development
remains obscure. In this paper we identified a distinct role of the Runx
family in sternal development. Interestingly, it has previously been
reported that mesenchymal-specific Sox9-deficient mice (Prx1
Cre/Sox9f/f mice) completely lack the sternum (Akiyama et al., 2002).
In addition, Sox5–/–; Sox6–/– mice have incomplete thoracic cage
closure (Smits et al., 2004). Together with the complete absence of the
sternum in Prx1 Runx1f/f/Runx2–/– mice, these observations uncover
a cascade of transcription factors necessary for sternal development.
Although Sox9, Sox5 and Sox6 are expressed in all mesenchymal
condensations (Akiyama et al., 2002; Smits et al., 2004), Runx1 is
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Fig. 4. Normal condensation but abolished
expression of Sox5 and Sox6 in the
prospective sternum of Prx1-Cre DKO mice.
(A) Histological analysis of axial sections of E13.5
mouse embryo prospective sternums. Upper and
bottom left, Alcian Blue staining; bottom right,
PNA staining. The bottom figures show high
magnification of each corresponding rectangle in
the upper panel. Note the PNA-positive
mesenchymal condensations in Prx1 DKO mice.
The diminished Alcian Blue staining in Prx1 DKO
mice suggests the impaired accumulation of
cartilage matrices. (B) In situ hybridization analysis
of E13.5 mouse embryo prospective sternums
(boxed area). In Prx1-Cre DKO mice, Sox9
expression in the prospective sternum (white box
and higher magnification in the right panel) is not
altered, whereas Sox5, Sox6 and a1(II) collagen
expression in the same area are markedly
decreased. Prx1 Runx1f/f mice and Prx1 DKO mice
denote Prx1-Cre; Runx1f/f mice and Prx1-Cre;












strongly and almost exclusively expressed in cells of the prospective
sternum, suggesting that Runx1 is particularly involved in sternal
morphogenesis. Analysis of the mutant mice generated for this study
confirms this hypothesis and indicates that Runx1 is important in
sternal morphogenesis by promoting chondrocyte differentiation.
Currently, the molecular mechanisms of the sternum-specific
expression of Runx1 are unknown.
Genetic hierarchy in chondrocyte lineage
commitment
Prx1 Runx1f/f/Runx2–/– mice have a phenotype resembling that of
Prx1 Cre/Sox9f/f mice in several respects but distinct in other ways
(Akiyama et al., 2002). Both mutants lack expression of Sox5 and
Sox6 and subsequent chondrocyte differentiation; however, Prx1
Cre/Sox9f/f mice lack mesenchymal condensations (Akiyama et al.,
2002), whereas Prx1 Runx1f/f/Runx2–/– mice develop clear
mesenchymal condensations (Fig. 4A). Moreover, in Prx1
Cre/Sox9f/f mice, Runx2 expression is abolished (Akiyama et al.,
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Fig. 5. Sox6 is a molecular target of Runx1 and Runx2 in
chondrocyte differentiation. (A,B) Real-time PCR analysis. (A) Runx1
and Runx2 induced the expression of Sox6 (left), Sox5 (middle) and
a1(II) collagen (right) in C3H10T1/2 cells. (B) The knockdown of Runx1
and Runx2 significantly decreased the expression of Sox6 and Sox5 in
C3H10T1/2 cells. (C) Schematic representation of the putative Runx-
binding site in the Sox6 promoter (top). Comparison of the sequence of
the putative Runx-binding site in the Sox6 promoter across different
species (bottom). Note the conservation of the binding site across
species. (D) EMSA. Nuclear extracts (NEs) from Runx1- (left) or Runx2-
(right) expressing COS cells formed a protein-DNA complex following
incubation with oligonucleotides encompassing the Runx binding site in
the Sox6 promoter (black arrowheads). NEs incubated with antibodies
against Runx1 or Runx2 showed supershifted bands (white
arrowheads). *, P<0.05 to control.
Fig. 6. Sox6 is a molecular target of Runx1 and Runx2 in
chondrocyte differentiation. (A) ChIP assay. An antibody against
Runx1 (left) or Runx2 (right) immunoprecipitated the Runx binding site
of the human Sox6 promoter (–494/–489) in HeLa cells overexpressing
Runx1 and Runx2 (top). The same antibody also immunoprecipitated
Runx binding site of the mouse Sox6 promoter (–454/–449) in
untransfected mesenchymal-chondrogenic C3H10T1/2 cells (middle)
and naive mouse primary sternal anlagen (bottom). (B) Sox6 promoter
activity in HeLa cells. Runx1 (left) or Runx2 (right) significantly increased
the activity of the 0.5 kb Sox6 promoter (pSox6 518-luc). This induction
was reduced by 50% by deleting (pSox6 467-luc, pSox6 518 del-luc) or
mutating (pSox6 518 mut-luc) the Runx binding site in the promoter.
*a: P<0.05 to control. *b: P<0.05 to pSox6 518-luc overexpressing
Runx protein. (C) Proposed mechanism: Runx1 and Runx2 cooperatively













2002). By contrast, Sox9 expression is clearly observed in Prx1
Runx1f/f/Runx2–/– mice (Fig. 4B). In Sox5–/–; Sox6–/– mice, Runx2
expression is observed in early mesenchymal condensations (Smits
et al., 2001). By contrast, in the current study, the expression of Sox5
and Sox6 was downregulated in Prx1 Runx1f/f/Runx2–/– mice (Fig.
4B). Taken together, these findings suggest that Runx1 and Runx2
are located between Sox9 and Sox5/6 in the genetic cascade,
although it is not clear whether Runx1 and Runx2 are direct targets
of Sox9. In our hands, the overexpression of Sox9 in HeLa cells or
mesenchymal cell lines did not induce Runx1 or Runx2 expression
(A.K. and S.T., unpublished observation), suggesting that the effect
of Sox9 on Runx1 or Runx2 expression is indirect. Because Sox5 and
Sox6 lack an activation domain, it is essential for them to have co-
regulators that transactivate their target genes (Lefebvre and Smits,
2005). Thus, it is tempting to hypothesize that Runx1 and/or Runx2
may be responsible for the transactivation function of Sox5 and
Sox6. Interestingly, whereas Sox5–/–; Sox6–/– mice have a defect in
sternal development, Sox5–/–; Sox6+/– mice and Sox5+/–; Sox6–/–
mice rather develop accelerated premature hypertrophy of sternal
chondrocytes (Smits et al., 2004). Therefore, sternal mesenchymal
cells require Sox5 and Sox6 for proper sternal development, but only
at a low dose.
Temporal but pivotal role of Runx1 in sternal
morphogenesis
In the current analysis, we demonstrate that the removal of both
Runx1 and Runx2 early during skeletogenesis caused a complete
loss of the sternum, whereas removal of Runx1 and Runx2 after the
formation of mesenchymal condensations did not affect the
development of the sternum. The fact that Prx1 Runx1f/+/Runx2–/–
mice developed an intermediate phenotype between Runx2–/– mice
and Prx1 Runx1f/f/Runx2–/– mice and that Prx1 Runx1f/f/Runx2+/–
mice also developed an intermediate phenotype between Prx1
Runx1f/f mice and Prx1 Runx1f/f/Runx2–/– mice suggests that Runx1
and Runx2 have redundant roles in sternal morphogenesis and
chondrocyte differentiation (Fig. 1A-D).
Interestingly, hypoxia induces chondrocyte differentiation and
prevents hypertrophy. Moreover, mice deficient in HIF-1a, an
indispensable factor in the response to hypoxia, have a defect in
chondroblast differentiation (Provot et al., 2007), although
mesenchymal condensations develop normally, which is reminiscent
of what occurs in Prx1 Runx1f/f/Runx2–/– mice. Moreover, Runx1 is
upregulated in hypoxic metatarsal culture, but interestingly, Runx2
expression is downregulated in this same culture (Provot et al.,
2007). Thus, these observations suggest a role of Runx1 in hypoxia-
induced chondrocyte differentiation.
Runx2 and chondrocyte lineage commitment
Runx2 is expressed in mesenchymal cells and is then turned off in
chondroblasts. Because Runx2 is expressed throughout
osteoblastic differentiation and is indispensable in the process,
Runx2 expression in mesenchymal cells has traditionally been
considered to be essential for osteoblastic lineage commitment
but not for chondrocyte lineage commitment (Ducy et al., 1997).
In this study, however, we clearly demonstrated that removing
Runx2 in addition to Runx1 results in the loss of chondrocyte
lineage commitment, at least in the sternum (Fig. 1A, Fig. 4).
Recently, the loss of b-catenin (Ctnnb1 – Mouse Genome
Informatics) in mesenchymal condensations was shown to cause
a lineage shift toward the chondrocyte lineage from the
osteoblastic lineage (Day et al., 2005; Hill et al., 2005).
Interestingly, the loss of b-catenin caused an increase in Runx2
and Sox9 expression (Hill et al., 2005). Taken together, these
observations suggest that, at the early mesenchymal condensation
stage, Runx2 works as a determinant for osteochondro progenitor
cell development and not specifically as a determinant of
osteoblast differentiation. It would be interesting to see whether
the loss of b-catenin in mesenchymal cells also upregulates
Runx1, which would result in the further induction of chondrocyte
differentiation.
Compensatory mechanism for the loss of Runx1
and Runx2 in chondrocyte differentiation in the
limbs
In the current study, the abnormal chondrocyte lineage commitment
in Prx1 Runx1f/f/Runx2–/– mice was restricted to the sternum (Fig.
1A,B), whereas chondrocyte differentiation was normal in the
limbs (Fig. 1A, and data not shown). Because chondrocyte lineage
commitment was normal throughout the bodies of Runx2–/–;
Runx3–/– mice, despite a slight delay in early skeletal limb
development, (Yoshida et al., 2004), it is possible that Runx1,
Runx2 and Runx3 have redundant roles in limb chondrocyte
development. Because Runx1 expression was not observed in
mesenchymal condensations in both the sternum and the limbs,
however, it is likely that molecule(s) other than Runx proteins
compensate for the loss of Runx2 and Runx3 in the skeletal limbs
of Runx2–/–; Runx3–/– mice. To date, several transcription factors
that regulate the commitment of mesenchymal cells to become
chondrocytes have been identified (ten Berge et al., 1998; LeClair
et al., 1999; Herbrand et al., 2002). Further elucidation is necessary
to identify the factors that compensate for the absence of the Runx
proteins.
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